The Uromigos

Bölümler

• Episode 510: ADCs in Prostate Cancer 15.06.2026 30dk

  Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.
• Episode 509: ASCO 2026 Review 08.06.2026 55dk

  This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent studies, controversies, and future directions in GU oncology.
• Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer 31.05.2026 39dk

  Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.
• Episode 507: ASCO 2026 - TALAPRO-3 30.05.2026 41dk

  Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.
• Episode 506: ASCO 2026 - How do we measure quality of life in GU patients? 30.05.2026 19dk

  This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer clinical trials, highlighting recent data, patient perspectives, and innovative approaches to assessment. Experts discuss the limitations of current tools, the importance of long-term follow-up, and future directions for integrating patient-centered metrics.
• Episode 505 : ASCO 2026 - RAMPART 30.05.2026 29dk

  James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.
• Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer 29.05.2026 40dk

  This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts discuss efficacy, safety, biomarkers, and future directions in bladder cancer treatment.
• Episode 499: APCCC 2026 - Radioligands in Prostate Cancer 25.05.2026 37dk

  This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, challenges, and future directions in radiopharmaceuticals.
• Episode 503: ASCO 2026 Preview 22.05.2026 1sa 22dk

  Silke joins Brian and Tom to discuss what to look for in GU cancers at ASCO 2026
• Episode 502: AUA 2026 and FDA bladder cancer meeting 20.05.2026 35dk

  In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of drug approvals, the importance of randomized trials, and the emerging data on Deltalimagene, a non-viral gene therapy. The conversation highlights the complexities of treatment options, the need for robust clinical trials, and the future landscape of bladder cancer therapies
• Episode 501: APCCC 2026 - Biochemically-relapsed Prostate cancer 18.05.2026 19dk

  Chuck Ryan from MSKCC joins us in Lugano for the final podcast from APCCC to talk about the ever-evolving space of BCR in prostate cancer.
• Episode 500: RAS Inhibition in Pancreatic Cancer (yes this is the Uromigos podcast..) 11.05.2026 35dk

  Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer ahead of the ASCO 2026 plenary phase 3 data. We discuss the RAS pathway, prior unsuccessful targeting efforts and nuances on response and resistance.
• Episode 498: APCCC 2026 - mCRPC 02.05.2026 21dk

  This APCCC podcast with Elena Castro features a detailed discussion on recent advances and ongoing debates in the treatment of castrate resistant prostate cancer (CRPC), including the placement of lutetium, biomarker-driven therapy, and emerging treatment options.
• Episode 497: Reflections on the capivasertib ODAC 01.05.2026 21dk

  This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-risk considerations, biomarker challenges, and regulatory perspectives.
• Episode 496: APCCC 2026 - mHSPC Landscape 01.05.2026 26dk

  Rob Jones joins us in Lugano at the APCCC Meeting to discuss areas of consensus and controversy in the mHSPC landscape including de-escalation strategies.
• Episode 495: APCCC 2026 - Locally-advanced Prostate Cancer 30.04.2026 31dk

  This episode with Piet Ost covers the latest insights from the APCCC conference in Lugano, focusing on locally advanced prostate cancer, biochemical relapse, and the role of PSMA PET imaging and biomarkers in treatment decisions.
• Episode 494: Duration of EVP in Multiple Urothelial Cancer Settings / Paper of the Month PPARG Inverse Agonist 27.04.2026 40dk

  Matt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on the PPARG inverse agonist in advanced bladder cancer.
• Episode 493: The Role of Chemotherapy in mHSPC 13.04.2026 47dk

  In the world of prostate cancer treatment, chemotherapy's role, especially in metastatic hormone-sensitive cases, remains a topic of much discussion and evolving understanding. In this podcast, we delve into the insights shared during a recent conversation with Dr. Deepak Kilari, a GU Medical Oncologist, exploring the nuances of chemotherapy in this context. We discuss key trials, shifting definitions of disease volume, and the implications for treatment decisions.
• Episode 492: Novel Biomarkers and Targets in Germ Cell Tumors 06.04.2026 33dk

  This podcast features Dr. Mike Glover from MDACC discussing recent advances in germ cell tumor research, focusing on novel biomarkers like microRNA and ctDNA, and emerging therapies targeting Claudin-6. The conversation explores how these innovations could transform diagnosis, prognosis, and treatment strategies.
• Episode 490: Systemic Therapy Only in Patients wtih MIBC 30.03.2026 48dk

  Laura Bukavina, Tyler Stewart and Amanda Nizam join Brian and Tom to discuss and debate a new clinical trial exploring EVP in MIBC with omission of cystectomy of clinical CR patients